Source: MarketWatch ↗
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
|
Translation unavailable. Please try again.
What the source reports
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
Read the original report on MarketWatch ↗